VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

Kyverna Therapeutics, Inc. (KYTX) Total Return Calculator with Dividends Reinvested

Kyverna Therapeutics, Inc.

Popular:

The total return for Kyverna Therapeutics, Inc. (KYTX) stock is +360.40% over the past 12 months. So far it's up 6.04% this year. The 5-year total return is -69.00%, meaning $10,000 invested in KYTX stock 5 years ago would be worth $3,100 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in KYTX 1 year ago, it would be worth $43,662 today — you'd have gained $33,662.

With Dividends Reinvested$43,662+336.62%

Price Only (No DRIP)$43,662+336.62%

Period2025-05-08 → 2026-05-07

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in KYTX

1Y$46,040+$36,040 (+360.4%)360.4% CAGR

3Y$3,100-$6,900 (-69.0%)-32.3% CAGR

5Y$3,100-$6,900 (-69.0%)-20.9% CAGR

10Y$3,100-$6,900 (-69.0%)-11.1% CAGR

15Y$3,100-$6,900 (-69.0%)-7.5% CAGR

20Y$3,100-$6,900 (-69.0%)-5.7% CAGR

30Y$3,100-$6,900 (-69.0%)-3.8% CAGR

Kyverna Therapeutics, Inc. did not pay dividends during this period. Total return = price return.

Loading KYTX total return...

As of 2026-05-08

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	+6.04%	—	+6.04%	—	$10,604
1Y	+360.40%	360.40%	+360.40%	—	$46,040
3Y	-69.00%	-32.32%	-69.00%	—	$3,100
5Y	-69.00%	-20.88%	-69.00%	—	$3,100
10Y	-69.00%	-11.05%	-69.00%	—	$3,100
15Y	-69.00%	-7.51%	-69.00%	—	$3,100
20Y	-69.00%	-5.69%	-69.00%	—	$3,100
30Y	-69.00%	-3.83%	-69.00%	—	$3,100

Risk & Highlights

Best Year+139.80%2025

Worst Year-87.53%2024

Max Drawdown-36.90%2025-12-16 → 2025-12-17 · Recovered 2026-04-20

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-6.39%	-6.39%	—	+0.41%	-6.8pp
2025	+139.80%	+139.80%	—	+16.64%	+123.2pp
2024	-87.53%	-87.53%	—	+24.00%	-111.5pp

KYTX outperformed the S&P 500 by 330.02pp over the past year (+360.40% vs +30.37%).

Loading summary...

KYTX Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
KYTXKyverna Therapeutics, Inc.	$407M	-0.3%	+6.0%	+360.4%	—	-69.0%	-69.0%	-69.0%
CABACabaletta Bio, Inc.	$409M	+30.3%	+81.0%	+244.8%	—	-65.8%	-58.2%	-60.0%
AUTLAutolus Therapeutics plc	$410M	+18.0%	-14.2%	+30.5%	—	-14.6%	-70.1%	-93.6%
IMVTImmunovant, Inc.	$5.5B	+10.6%	+5.1%	+96.1%	—	+40.9%	+62.4%	+173.6%
BEAMBeam Therapeutics Inc.	$3.2B	+28.5%	+16.0%	+93.9%	—	-5.6%	-55.6%	+67.8%
LEGNLegend Biotech Corporation	$5.3B	+58.8%	+32.8%	-9.2%	—	-58.4%	-0.0%	-22.8%
CRSPCRISPR Therapeutics AG	$5.1B	+5.5%	-2.5%	+53.1%	—	-6.3%	-51.3%	+272.0%
NTLAIntellia Therapeutics, Inc.	$1.6B	+1.2%	+48.9%	+88.1%	—	-68.3%	-79.8%	-42.9%
EDITEditas Medicine, Inc.	$297M	+10.6%	+47.8%	+127.8%	—	-68.5%	-91.1%	-90.0%
FATEFate Therapeutics, Inc.	$280M	+111.3%	+145.5%	+143.0%	—	-55.4%	-96.8%	+40.5%
ALLOAllogene Therapeutics, Inc.	$521M	-13.4%	+68.1%	+89.2%	—	-64.1%	-92.4%	-90.9%

Compare:KYTX vs CABA KYTX vs AUTL KYTX vs IMVT KYTX vs CABA vs AUTL

About KYTX Dividend Returns

Kyverna Therapeutics, Inc. (KYTX) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of KYTX over the past year?

Kyverna Therapeutics, Inc. (KYTX) delivered a return of 360.40% over the past year. Since KYTX does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in KYTX be worth today?

A $10,000 investment in Kyverna Therapeutics, Inc. one year ago would be worth $46,040 today, representing a gain of $36,040.

Q3Does KYTX pay dividends?

Kyverna Therapeutics, Inc. (KYTX) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For KYTX, the total return equals the price-only return.

Q4Did KYTX beat the S&P 500?

Yes, Kyverna Therapeutics, Inc. (KYTX) outperformed the S&P 500 by 330.02 percentage points over the past year. KYTX delivered a total return of 360.40%, compared to the S&P 500's 30.37%. This 330.02pp alpha means investors in KYTX earned more than a passive S&P 500 index fund.

Q5What is KYTX's worst drawdown?

Kyverna Therapeutics, Inc. (KYTX) experienced a maximum drawdown of -36.90% over the past year, declining from its peak on 2025-12-16 to its trough on 2025-12-17. The stock recovered to its prior peak by 2026-04-20. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is KYTX's long-term total return over 10, 20, or 30 years?

Here are Kyverna Therapeutics, Inc. (KYTX)'s long-term returns with dividends reinvested. Over 10 years, the total return is -69.0% (-11.1% CAGR) — $10,000 would have grown to $3,100. Over 20 years: -69.0% total return (-5.7% CAGR) — $10,000 → $3,100. Over 30 years: -69.0% total return (-3.8% CAGR) — $10,000 → $3,100. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was KYTX's best and worst year?

Kyverna Therapeutics, Inc.'s best calendar year was 2025 with a total return of 139.8%. Its worst year was 2024 with a total return of -87.5%. This range shows the volatility investors should expect — the difference between the best and worst year is 227.3 percentage points.